Journal article
Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial
Abstract
Oral anticoagulation is the mainstay of therapy for stroke prevention in patients with atrial fibrillation. Vitamin K antagonists such as warfarin reduce the risk of cardioembolic stroke by approximately two-thirds compared with no treatment, but are limited by their unpredictable anticoagulant effect and narrow therapeutic index. Warfarin therapy requires routine coagulation monitoring, which is inconvenient for patients and costly for the …
Authors
Paikin JS; Haroun MJ; Eikelboom JW
Journal
Expert Review of Cardiovascular Therapy, Vol. 9, No. 3, pp. 279–286
Publisher
Taylor & Francis
Publication Date
March 2011
DOI
10.1586/erc.11.21
ISSN
1477-9072